Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Earnings & Valuation
This table compares Prestige Consumer Healthcare and Unicycive Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prestige Consumer Healthcare | $1.09 billion | 2.05 | $190.30 million | $3.57 | 13.16 |
| Unicycive Therapeutics | $680,000.00 | 216.66 | -$26.56 million | ($1.75) | -3.02 |
Volatility and Risk
Prestige Consumer Healthcare has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Prestige Consumer Healthcare and Unicycive Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prestige Consumer Healthcare | 1 | 3 | 2 | 0 | 2.17 |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Prestige Consumer Healthcare presently has a consensus target price of $70.75, suggesting a potential upside of 50.55%. Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 254.44%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Prestige Consumer Healthcare.
Profitability
This table compares Prestige Consumer Healthcare and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prestige Consumer Healthcare | 15.57% | 11.39% | 5.66% |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
Institutional and Insider Ownership
100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Prestige Consumer Healthcare beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
